Advances in Medical Imaging: Aptamer- and Peptide-Targeted MRI and CT Contrast Agents

Computed tomography (CT) and magnetic resonance imaging (MRI) are among the most well-established modalities in the field of noninvasive medical imaging. Despite being powerful tools, both suffer from a number of limitations and often fall short when it comes to full delineation of pathological tiss...

Full description

Saved in:
Bibliographic Details
Published in:ACS omega 2020-09, Vol.5 (36), p.22691-22701
Main Authors: Koudrina, Anna, DeRosa, Maria C
Format: Article
Language:English
Subjects:
Mini-Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a499t-5d5b6ea7027786b0046c061d678c3b370fa66aa7ed346957fab79494756eda13
cites cdi_FETCH-LOGICAL-a499t-5d5b6ea7027786b0046c061d678c3b370fa66aa7ed346957fab79494756eda13
container_end_page 22701
container_issue 36
container_start_page 22691
container_title ACS omega
container_volume 5
creator Koudrina, Anna
DeRosa, Maria C
description Computed tomography (CT) and magnetic resonance imaging (MRI) are among the most well-established modalities in the field of noninvasive medical imaging. Despite being powerful tools, both suffer from a number of limitations and often fall short when it comes to full delineation of pathological tissues. Since its conception, molecular imaging has been commonly utilized to further the understanding of disease progression, as well as monitor treatment efficacy. This has naturally led to the advancement of the field of targeted imaging. Targeted imaging research is currently dominated by ligand-modified contrast media for applications in MRI and CT imaging. Although a plethora of targeting ligands exist, a fine balance between their size and target binding efficiency must be considered. This review will focus on aptamer- and peptide-modified contrast agents, outlining selected formulations developed in recent years while highlighting the advantages offered by these targeting ligands.
doi_str_mv 10.1021/acsomega.0c02650
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_445542262f9a4b10b7df99fce6dcca52</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_445542262f9a4b10b7df99fce6dcca52</doaj_id><sourcerecordid>2444616758</sourcerecordid><originalsourceid>FETCH-LOGICAL-a499t-5d5b6ea7027786b0046c061d678c3b370fa66aa7ed346957fab79494756eda13</originalsourceid><addsrcrecordid>eNp1kc1P3DAQxS3UChBw76nKsYeG2o4_4h4qrVb9WAlUhLZna2JP0qwSe2tnkfjvG9gFwYHTWDPv_WzPI-QDo5eMcvYFXI4jdnBJHeVK0iNyyoWmJatE9e7F-YRc5LyhlDJV85qrY3JScSMFY-qU_Fn4OwgOc9GH4hp972AoViN0fei-FovtBCOmsoDgixvcTr3Hcg2pwwl9cX27ehws18UyhilBnopFh2HK5-R9C0PGi0M9I-sf39fLX-XV75-r5eKqBGHMVEovG4WgKde6Vg2lQjmqmFe6dlVTadqCUgAafSWUkbqFRhthhJYKPbDqjKz2WB9hY7epHyHd2wi9fWzE1FlIU-8GtEJIKThXvDUgGkYb7VtjWofKOweSz6xve9Z214zoHT58aHgFfT0J_V_bxTurxbxLSWfApwMgxX87zJMd--xwGCBg3GXLhRCKKS3rWUr3Updizgnb52sYtQ_Z2qds7SHb2fLx5fOeDU9JzoLPe8FstZu4S2Fe_Nu8_1XqrvA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2444616758</pqid></control><display><type>article</type><title>Advances in Medical Imaging: Aptamer- and Peptide-Targeted MRI and CT Contrast Agents</title><source>American Chemical Society (ACS) Open Access</source><source>PubMed Central</source><creator>Koudrina, Anna ; DeRosa, Maria C</creator><creatorcontrib>Koudrina, Anna ; DeRosa, Maria C</creatorcontrib><description>Computed tomography (CT) and magnetic resonance imaging (MRI) are among the most well-established modalities in the field of noninvasive medical imaging. Despite being powerful tools, both suffer from a number of limitations and often fall short when it comes to full delineation of pathological tissues. Since its conception, molecular imaging has been commonly utilized to further the understanding of disease progression, as well as monitor treatment efficacy. This has naturally led to the advancement of the field of targeted imaging. Targeted imaging research is currently dominated by ligand-modified contrast media for applications in MRI and CT imaging. Although a plethora of targeting ligands exist, a fine balance between their size and target binding efficiency must be considered. This review will focus on aptamer- and peptide-modified contrast agents, outlining selected formulations developed in recent years while highlighting the advantages offered by these targeting ligands.</description><identifier>ISSN: 2470-1343</identifier><identifier>EISSN: 2470-1343</identifier><identifier>DOI: 10.1021/acsomega.0c02650</identifier><identifier>PMID: 32954116</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Mini-Review</subject><ispartof>ACS omega, 2020-09, Vol.5 (36), p.22691-22701</ispartof><rights>Copyright © 2020 American Chemical Society.</rights><rights>Copyright © 2020 American Chemical Society 2020 American Chemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a499t-5d5b6ea7027786b0046c061d678c3b370fa66aa7ed346957fab79494756eda13</citedby><cites>FETCH-LOGICAL-a499t-5d5b6ea7027786b0046c061d678c3b370fa66aa7ed346957fab79494756eda13</cites><orcidid>0000-0003-1868-6357</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acsomega.0c02650$$EPDF$$P50$$Gacs$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acsomega.0c02650$$EHTML$$P50$$Gacs$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27079,27923,27924,53790,53792,56761,56811</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32954116$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koudrina, Anna</creatorcontrib><creatorcontrib>DeRosa, Maria C</creatorcontrib><title>Advances in Medical Imaging: Aptamer- and Peptide-Targeted MRI and CT Contrast Agents</title><title>ACS omega</title><addtitle>ACS Omega</addtitle><description>Computed tomography (CT) and magnetic resonance imaging (MRI) are among the most well-established modalities in the field of noninvasive medical imaging. Despite being powerful tools, both suffer from a number of limitations and often fall short when it comes to full delineation of pathological tissues. Since its conception, molecular imaging has been commonly utilized to further the understanding of disease progression, as well as monitor treatment efficacy. This has naturally led to the advancement of the field of targeted imaging. Targeted imaging research is currently dominated by ligand-modified contrast media for applications in MRI and CT imaging. Although a plethora of targeting ligands exist, a fine balance between their size and target binding efficiency must be considered. This review will focus on aptamer- and peptide-modified contrast agents, outlining selected formulations developed in recent years while highlighting the advantages offered by these targeting ligands.</description><subject>Mini-Review</subject><issn>2470-1343</issn><issn>2470-1343</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>N~.</sourceid><sourceid>DOA</sourceid><recordid>eNp1kc1P3DAQxS3UChBw76nKsYeG2o4_4h4qrVb9WAlUhLZna2JP0qwSe2tnkfjvG9gFwYHTWDPv_WzPI-QDo5eMcvYFXI4jdnBJHeVK0iNyyoWmJatE9e7F-YRc5LyhlDJV85qrY3JScSMFY-qU_Fn4OwgOc9GH4hp972AoViN0fei-FovtBCOmsoDgixvcTr3Hcg2pwwl9cX27ehws18UyhilBnopFh2HK5-R9C0PGi0M9I-sf39fLX-XV75-r5eKqBGHMVEovG4WgKde6Vg2lQjmqmFe6dlVTadqCUgAafSWUkbqFRhthhJYKPbDqjKz2WB9hY7epHyHd2wi9fWzE1FlIU-8GtEJIKThXvDUgGkYb7VtjWofKOweSz6xve9Z214zoHT58aHgFfT0J_V_bxTurxbxLSWfApwMgxX87zJMd--xwGCBg3GXLhRCKKS3rWUr3Updizgnb52sYtQ_Z2qds7SHb2fLx5fOeDU9JzoLPe8FstZu4S2Fe_Nu8_1XqrvA</recordid><startdate>20200915</startdate><enddate>20200915</enddate><creator>Koudrina, Anna</creator><creator>DeRosa, Maria C</creator><general>American Chemical Society</general><scope>N~.</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1868-6357</orcidid></search><sort><creationdate>20200915</creationdate><title>Advances in Medical Imaging: Aptamer- and Peptide-Targeted MRI and CT Contrast Agents</title><author>Koudrina, Anna ; DeRosa, Maria C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a499t-5d5b6ea7027786b0046c061d678c3b370fa66aa7ed346957fab79494756eda13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Mini-Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koudrina, Anna</creatorcontrib><creatorcontrib>DeRosa, Maria C</creatorcontrib><collection>American Chemical Society (ACS) Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>ACS omega</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koudrina, Anna</au><au>DeRosa, Maria C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advances in Medical Imaging: Aptamer- and Peptide-Targeted MRI and CT Contrast Agents</atitle><jtitle>ACS omega</jtitle><addtitle>ACS Omega</addtitle><date>2020-09-15</date><risdate>2020</risdate><volume>5</volume><issue>36</issue><spage>22691</spage><epage>22701</epage><pages>22691-22701</pages><issn>2470-1343</issn><eissn>2470-1343</eissn><abstract>Computed tomography (CT) and magnetic resonance imaging (MRI) are among the most well-established modalities in the field of noninvasive medical imaging. Despite being powerful tools, both suffer from a number of limitations and often fall short when it comes to full delineation of pathological tissues. Since its conception, molecular imaging has been commonly utilized to further the understanding of disease progression, as well as monitor treatment efficacy. This has naturally led to the advancement of the field of targeted imaging. Targeted imaging research is currently dominated by ligand-modified contrast media for applications in MRI and CT imaging. Although a plethora of targeting ligands exist, a fine balance between their size and target binding efficiency must be considered. This review will focus on aptamer- and peptide-modified contrast agents, outlining selected formulations developed in recent years while highlighting the advantages offered by these targeting ligands.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>32954116</pmid><doi>10.1021/acsomega.0c02650</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-1868-6357</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2470-1343
ispartof ACS omega, 2020-09, Vol.5 (36), p.22691-22701
issn 2470-1343
2470-1343
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_445542262f9a4b10b7df99fce6dcca52
source American Chemical Society (ACS) Open Access; PubMed Central
subjects Mini-Review
title Advances in Medical Imaging: Aptamer- and Peptide-Targeted MRI and CT Contrast Agents
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T23%3A49%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advances%20in%20Medical%20Imaging:%20Aptamer-%20and%20Peptide-Targeted%20MRI%20and%20CT%20Contrast%20Agents&rft.jtitle=ACS%20omega&rft.au=Koudrina,%20Anna&rft.date=2020-09-15&rft.volume=5&rft.issue=36&rft.spage=22691&rft.epage=22701&rft.pages=22691-22701&rft.issn=2470-1343&rft.eissn=2470-1343&rft_id=info:doi/10.1021/acsomega.0c02650&rft_dat=%3Cproquest_doaj_%3E2444616758%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a499t-5d5b6ea7027786b0046c061d678c3b370fa66aa7ed346957fab79494756eda13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2444616758&rft_id=info:pmid/32954116&rfr_iscdi=true